| Serial Number | 79309216 |
| Word Mark | MEDIGENE IMMUNOTHERAPIES |
| Filing Date | Tuesday, February 23, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 27, 2022 |
| Registration Number | 6932587 |
| Registration Date | Tuesday, December 27, 2022 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 11, 2022 |
| Goods and Services | Medicines for humans and animals, vaccines, serums for medical purposes, and diagnostic preparations for medical purposes for treating cancer, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptors, and genetically modified cells for determining the type and existence of a tumour in a patient, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins and cells, namely, immune cells carrying a target specific effector protein, protein conjugates, peptides, enzymes and enzyme preparations, in particular antibodies and t-cell proteins, all for medical purposes; t-cells, dendritic cells other immune system cells, and viruses, all for medical purposes;plant extracts for medical purposes; medicines, vaccines, adjuvants, serums all for immunotherapy and the treatment of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods |
| Pseudo Mark | MEDI GENE IMMUNOTHERAPY'S |
| Goods and Services | Medical analysis and medical consulting in connection with the treatment of individuals, in particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and immunotherapy |
| Disclaimer with Predetermined Text | "IMMUNOTHERAPIES" |
| Goods and Services | Custom molecular biology and biotechnology laboratory services, in particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods to the specifications of others, and in the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 23, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 23, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 23, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Medigene Immunotherapies GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | DE |
| Party Name | Medigene Immunotherapies GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | DE |
| Party Name | Medigene Immunotherapies GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | DE |
| Event Date | Event Description |
| Monday, May 1, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, April 6, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, April 6, 2023 | FINAL DISPOSITION PROCESSED |
| Monday, March 27, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, December 27, 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, December 27, 2022 | REGISTERED-PRINCIPAL REGISTER |
| Monday, October 17, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Tuesday, October 11, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 11, 2022 | PUBLISHED FOR OPPOSITION |
| Monday, October 10, 2022 | NOTIFICATION PROCESSED BY IB |
| Wednesday, September 28, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, September 28, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Wednesday, September 21, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, September 21, 2022 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, September 21, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, September 7, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 7, 2022 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, September 7, 2022 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, September 7, 2022 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, September 7, 2022 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, April 14, 2022 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, April 14, 2022 | FINAL REFUSAL E-MAILED |
| Thursday, April 14, 2022 | FINAL REFUSAL WRITTEN |
| Wednesday, March 30, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, March 30, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, March 30, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, October 30, 2021 | REFUSAL PROCESSED BY IB |
| Friday, October 1, 2021 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, October 1, 2021 | REFUSAL PROCESSED BY MPU |
| Monday, September 27, 2021 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Sunday, September 26, 2021 | NON-FINAL ACTION WRITTEN |
| Friday, September 17, 2021 | ASSIGNED TO EXAMINER |
| Tuesday, April 27, 2021 | APPLICATION FILING RECEIPT MAILED |
| Friday, April 23, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, April 22, 2021 | SN ASSIGNED FOR SECT 66A APPL FROM IB |